NCT06518122

A Study to Evaluate the Drug-drug Interaction and Safety Between HCP1306, RLD2302 and RLD2102 in Healthy Volunteers

A Randomized, Open Label, Multiple Dose, Crossover Clinical Trial to Evaluate the Drug-drug Interaction and Safety Between HCP1306, RLD2302 and RLD2102 in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 66 (actual)
• Sponsor: Hanmi Pharmaceutical Company Limited · Industry
• Sex: All
• Age: 19 Years – 54 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the drug-drug interaction and safety between HCP1306, RLD2302 and RLD2102 in healthy volunteers.

Detailed description

\[PART A\] To evaluate the drug-drug interaction and safety between HCP1306, RLD2302 \[PART B\] To evaluate the drug-drug interaction and safety between HCP1306, RLD2302, RLD2102

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	HCP1306	Take it once a day per period.
DRUG	RLD2302	Take it once a day per period.
DRUG	RLD2102	Take it once a day per period

Timeline

• Start date: 2024-09-01
• Primary completion: 2025-01-03
• Completion: 2025-01-03
• First posted: 2024-07-24
• Last updated: 2025-02-20

Locations

1 site across 1 country: South Korea